Table 5.
Distribution of patients by different acute and chronic health and risk conditions stratified to pharmacologic cardioversion success.
| No success (N = 63) vs. Success (N = 167) | P | ||
|---|---|---|---|
| Demographics | |||
| Age, median (IQR) | 65 (49–70) | 60 (49–68) | 0.10 |
| Female sex, n (%) | 20 (32%) | 57 (34%) | 0.76 |
| Body mass index, median (IQR) | 26 (23–29) | 27 (25–30) | 0.35 |
| Chronic health conditions and risk factors | |||
| Coronary artery disease, n (%) | 6 (10%) | 11 (7%) | 0.57 |
| Impaired left ventricular function, n (%) | 13 (21%) | 12 (7%) | 0.007 |
| Left atrial enlargement, n (%) | 32 (51%) | 71 (43%) | 0.53 |
| NT-proBNP, median (IQR) | 518 (160–1125) | 428 (112–1086) | 0.55 |
| Persistent atrial fibrillation, n (%) | 49 (78%) | 96 (58%) | 0.006 |
| Previous ablation therapy, n (%) | 17 (27%) | 27 (16%) | 0.09 |
| Vital signs and duration of arrhythmia | |||
| Systolic blood pressure, median (IQR) | 130 (120–140) | 130 (120–140) | 0.89 |
| Heart rate, median (IQR) | 120 (102–140) | 124 (110–140) | 0.92 |
| Duration of episode in hours, median (IQR) | 6 (3−13) | 6 (3−12) | 0.71 |
| Concomitant antiarrhythmic therapy | |||
| Class III antiarrhythmic agent, n (%) | 12 (19%) | 30 (18%) | 0.85 |
Unless otherwise indicated, data are numbers (percentages); IQR = interquartile range; n = number, NT-proBNP = N-terminal pro b-type natriuretic peptide.